LB Pharmaceuticals Inc (LBRX)
Nasdaq: LBRX · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2016
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 |
| Report filed | Mar 26, 2026 | · |
| Research and development | 16,744,000 | 51,171,000 |
| General and administrative | 13,660,000 | 13,659,000 |
| Total operating expenses | 30,404,000 | 64,830,000 |
| Interest and investment income | 3,920,000 | 1,721,000 |
| Total non-operating income (expense) | 5,200,000 | 1,729,000 |
| Income before income taxes | -25,204,000 | -63,101,000 |
| Income tax expense | 1,000 | 1,000 |
| Net income | -25,205,000 | -63,102,000 |
| Net income to common shareholders | -25,205 | -63,102 |
| Earnings per share, basic | -3.13 | -176.15 |
| Earnings per share, diluted | -3.13 | -176.15 |
| Weighted average shares, basic | 8,045,145 | 358,229 |
| Weighted average shares, diluted | 8,045,145 | 358,229 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding